Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sarcoma Alliance for Research through Collaboration
Patients with a diagnosis of early-stage uterine leiomyosarcoma have a 70% chance of relapse or recurrence of their disease. Patients enrolled in this trial will receive 4 cycles of gemcitabine and docetaxel followed by 4 cycles of adriamycin. Following completion of chemotherapy, they will be have repeat imaging at regular intervals to monitor for disease recurrence along with periodic clinical evaluations.
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
≥ 18 years of age
high risk uterine LMS, FIGO stage I or II
pathology review of LMS high grade and /or mitotic rate greater than or equal to 5 mitoses/10 hpf
no longer than 12 weeks from surgical resection of cancer
no evidence of residual disease
ECOG 0 or 1
ANC ≥ 1,500, hemoglobin ≥ 8.0, platelets ≥100,000
creatinine ≤ 1.5 x institutional upper limits of normal
adequate liver function
neuropathy (sensory and motor) ≤ CTC grade 1
negative pregnancy test
signed consent
You may not be if
patients with other invasive malignancies
prior therapy with gemcitabine or docetaxel or doxorubicin
hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80
women who are breast feeding
cardiac ejection fraction \<50%
prior pelvic irradiation
treatment with hormone replacement or anti-hormonal agents or other cytotoxic agents
Clareo Health | Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma
